Last reviewed · How we verify
NCT06676813
Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.
NA trial testing Alternate day fasting in Non Alcoholic Steatohepatitis in 72 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Institute of Liver and Biliary Sciences, India |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 1 July 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across India |
Drugs / interventions tested
- Alternate day fasting
Conditions studied
- Non Alcoholic Steatohepatitis — all drugs for Non Alcoholic Steatohepatitis →
Sponsor
Institute of Liver and Biliary Sciences, India
Who can join
Adults 18 to 65, any sex, with Non Alcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aims of this study are as follows: To compare the role of alternate-day fasting over standard medical management alone to reverse NASH.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06676813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alternate day fasting
Trials testing the same drug.
- NCT04004403 — Alternate Day Fasting, Exercise, and NAFLD · NA · completed
- NCT03528317 — Alternate Day Fasting Combined With a High Protein Background Diet · NA · completed
Other recruiting trials for Non Alcoholic Steatohepatitis
Currently open trials in the same condition.
- NCT05463796 — InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer · recruiting
- NCT05821010 — Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis · Phase 2 · recruiting
- NCT05574036 — Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia · Phase 2 · active not recruiting
Other Institute of Liver and Biliary Sciences, India trials
Trials by the same sponsor.
- NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
- NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
- NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06676813 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06676813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing